Literature DB >> 9180088

Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders.

L Side1, B Taylor, M Cayouette, E Conner, P Thompson, M Luce, K Shannon.   

Abstract

BACKGROUND: The risk of malignant myeloid disorders in young children with neurofibromatosis type 1 is 200 to 500 times the normal risk. The gene for neurofibromatosis type 1 (NF1) encodes neurofibromin, a protein that negatively regulates signals transduced by Ras proteins. Genetic and biochemical data support the hypothesis that NF1 functions as a tumor-suppressor gene in immature myeloid cells, but inactivation of both NF1 alleles has not been demonstrated in leukemic cells from patients with neurofibromatosis type 1.
METHODS: Using an in vitro transcription and translation system, we screened bone marrow samples from 18 children with neurofibromatosis type 1 and myeloid disorders for NF1 mutations that cause a truncated protein. Mutations were confirmed by direct sequencing of genomic DNA from the patients, and from their affected parents, in cases of familial neurofibromatosis type 1.
RESULTS: Specimens from 9 of the 18 children contained abnormal peptide fragments, and truncating mutations of the NF1 gene were found in specimens from 8 of these children. The normal NF1 allele was absent in bone marrow samples from five of the eight children. We detected the same mutation in DNA from the affected parent of each child with familial neurofibromatosis type 1.
CONCLUSIONS: Both alleles of the NF1 gene are inactivated in leukemic cells in some patients with neurofibromatosis type 1. NF1 appears to function as a tumor-suppressor gene in immature myeloid cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9180088     DOI: 10.1056/NEJM199706123362404

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  68 in total

1.  NF1 inactivation in adult acute myelogenous leukemia.

Authors:  Brian Parkin; Peter Ouillette; Yin Wang; Yan Liu; Whitney Wright; Diane Roulston; Anjali Purkayastha; Amanda Dressel; Judith Karp; Paula Bockenstedt; Ammar Al-Zoubi; Moshe Talpaz; Lisa Kujawski; Yang Liu; Kerby Shedden; Sajid Shakhan; Cheng Li; Harry Erba; Sami N Malek
Journal:  Clin Cancer Res       Date:  2010-05-26       Impact factor: 12.531

Review 2.  RAS inhibitors in hematologic cancers: biologic considerations and clinical applications.

Authors:  D M Beaupre; R Kurzrock
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 3.  The NF1 somatic mutational landscape in sporadic human cancers.

Authors:  Charlotte Philpott; Hannah Tovell; Ian M Frayling; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2017-06-21       Impact factor: 4.639

4.  Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium.

Authors:  Rebecca J Chan; Todd Cooper; Christian P Kratz; Brian Weiss; Mignon L Loh
Journal:  Leuk Res       Date:  2008-10-26       Impact factor: 3.156

Review 5.  Mosaic RASopathies.

Authors:  Christian Hafner; Leopold Groesser
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

6.  Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk.

Authors:  Karl Staser; Su-Jung Park; Steven D Rhodes; Yi Zeng; Yong Zheng He; Matthew A Shew; Jeffrey R Gehlhausen; Donna Cerabona; Keshav Menon; Shi Chen; Zejin Sun; Jin Yuan; David A Ingram; Grzegorz Nalepa; Feng-Chun Yang; D Wade Clapp
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

7.  Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.

Authors:  Tiffany Chang; Kimberly Krisman; Emily Harding Theobald; Jin Xu; Jon Akutagawa; Jennifer O Lauchle; Scott Kogan; Benjamin S Braun; Kevin Shannon
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

8.  Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1.

Authors:  Doris Steinemann; Larissa Arning; Inka Praulich; Manfred Stuhrmann; Henrik Hasle; Jan Stary; Brigitte Schlegelberger; Charlotte M Niemeyer; Christian Flotho
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

9.  Genome wide molecular analysis of minimally differentiated acute myeloid leukemia.

Authors:  Fernando P G Silva; Inês Almeida; Bruno Morolli; Geeske Brouwer-Mandema; Hans Wessels; Rolf Vossen; Harry Vrieling; Erik W A Marijt; Peter J M Valk; Hanneke C Kluin-Nelemans; Wolfgang R Sperr; Wolf-Dieter Ludwig; Micheline Giphart-Gassler
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

Review 10.  Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?

Authors:  Stephanie Beurlet; Christine Chomienne; Rose Ann Padua
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.